StockData
SLXNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31Also trades as SLXNW

Silexion Therapeutics Corp

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026
$0.15+0.00 (0.00%)

Close on Oct 19, 2026

Market cap
$105.17K
P/E (TTM)
0.0
Dividend yield
–

Silexion Therapeutics Corp revenue by segment

No segment breakdown reported

Silexion Therapeutics does not break out revenue by segment, region or product in the tagged data of its filings for this period type.